Sam-A Pharm Valuation

Is A009300 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of A009300 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: A009300 (₩17550) is trading below our estimate of fair value (₩279824.02)

Significantly Below Fair Value: A009300 is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for A009300?

Key metric: As A009300 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for A009300. This is calculated by dividing A009300's market cap by their current earnings.
What is A009300's PE Ratio?
PE Ratio	4.7x
Earnings	₩22.77b
Market Cap	₩107.42b

A009300 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	0.4x
Enterprise Value/EBITDA	1.5x
PEG Ratio	n/a

Price to Earnings Ratio vs Peers

How does A009300's PE Ratio compare to its peers?

The above table shows the PE ratio for A009300 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PE	Estimated Growth	Market Cap
Peer Average	8.4x
A330350 WITHUS PHARMACEUTICALLTD	13.2x	n/a	₩89.0b
A066700 Theragen EtexLtd	4x	n/a	₩108.3b
A006620 DongKoo Bio & Pharma	10.7x	n/a	₩139.0b
A001540 Ahn-Gook Pharmaceutical	5.5x	n/a	₩78.8b
A009300 Sam-A Pharm	4.7x	n/a	₩107.1b

Price-To-Earnings vs Peers: A009300 is good value based on its Price-To-Earnings Ratio (4.7x) compared to the peer average (8.4x).

Price to Earnings Ratio vs Industry

How does A009300's PE Ratio compare vs other companies in the KR Pharmaceuticals Industry?

1 Company	Price / Earnings	Estimated Growth	Market Cap
A007370 Jin Yang Pharmaceutical	2.4x	n/a	US$48.11m

No more companies available in this PE range

1 Company		Estimated Growth	Market Cap

No more companies

Price-To-Earnings vs Industry: A009300 is good value based on its Price-To-Earnings Ratio (4.7x) compared to the KR Pharmaceuticals industry average (11.3x).

Price to Earnings Ratio vs Fair Ratio

What is A009300's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

A009300 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio	4.7x
Fair PE Ratio	n/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate A009300's Price-To-Earnings Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

J2KBIO

₩54.5b

A bio venture company, provides active ingredients for cosmetics, functional food, and household products from natural materials and microbial fermentation.

A420570

₩9,830.00

6.0%

n/a

Hugel

₩3.0t

Develops and manufactures biopharmaceuticals in South Korea and internationally.

A145020

₩268,000.00

-3.4%

75.9%

Dong-A ST

₩544.1b

Develops, manufactures, and markets pharmaceutical products in South Korea and internationally.

A170900

₩62,300.00

-2.0%

8.6%